J B Wong

Summary

Affiliation: Rhode Island Hospital
Country: USA

Publications

  1. ncbi request reprint Pharmacogenomics of hepatitis C and decision analysis: a glimpse into the future
    John B Wong
    Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Tufts University School of Medicine, 750 Washington Street, Boston, MA 02111, USA
    Hepatology 36:252-4. 2002
  2. ncbi request reprint Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis
    John B Wong
    Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Med 113:400-8. 2002
  3. pmc Estimating future hepatitis C morbidity, mortality, and costs in the United States
    J B Wong
    Department of Medicine, New England Medical Center, Tupper Research Institute, Tufts University School of Medicine, Boston, Mass, USA
    Am J Public Health 90:1562-9. 2000
  4. ncbi request reprint Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis
    J B Wong
    New England Medical Center, 750 Washington Street, Box 302, Boston, MA 02111, USA
    Ann Intern Med 133:665-75. 2000
  5. ncbi request reprint Long-term morbidity, mortality, and economics of rheumatoid arthritis
    J B Wong
    New England Medical Center, Boston, MA 02111, USA
    Arthritis Rheum 44:2746-9. 2001
  6. ncbi request reprint Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs
    J B Wong
    Department of Medicine, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    JAMA 280:2088-93. 1998
  7. pmc Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C
    U Siebert
    Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
    Gut 52:425-32. 2003
  8. ncbi request reprint Patient-specific decisions about hormone replacement therapy in postmenopausal women
    N F Col
    Division of Clinical Decision Making, Informatics, and Telemedicine, Department of Medicine, New England Medical Center and Tufts University School of Medicine, Boston, Mass 02111, USA
    JAMA 277:1140-7. 1997
  9. ncbi request reprint Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium
    J B Wong
    Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Boston, Ma U S A Department of Medicine, Divison of Hepatology, Catholic University Hospitals, Leuven, Belgium
    Acta Gastroenterol Belg 65:110-11. 2002
  10. ncbi request reprint Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis
    S J Cheng
    New England Medical Center, Tufts University School of Medicine, 750 Washington St, PO Box 302, Boston, MA 02111, USA
    Transplantation 72:861-8. 2001

Collaborators

Detail Information

Publications32

  1. ncbi request reprint Pharmacogenomics of hepatitis C and decision analysis: a glimpse into the future
    John B Wong
    Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Tufts University School of Medicine, 750 Washington Street, Boston, MA 02111, USA
    Hepatology 36:252-4. 2002
  2. ncbi request reprint Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis
    John B Wong
    Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Med 113:400-8. 2002
    ..To estimate the cost-effectiveness of infliximab plus methotrexate for active, refractory rheumatoid arthritis...
  3. pmc Estimating future hepatitis C morbidity, mortality, and costs in the United States
    J B Wong
    Department of Medicine, New England Medical Center, Tupper Research Institute, Tufts University School of Medicine, Boston, Mass, USA
    Am J Public Health 90:1562-9. 2000
    ..This study estimated future morbidity, mortality, and costs resulting from hepatitis C virus (HCV)...
  4. ncbi request reprint Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis
    J B Wong
    New England Medical Center, 750 Washington Street, Box 302, Boston, MA 02111, USA
    Ann Intern Med 133:665-75. 2000
    ..Not all patients with histologically mild chronic hepatitis C progress to cirrhosis...
  5. ncbi request reprint Long-term morbidity, mortality, and economics of rheumatoid arthritis
    J B Wong
    New England Medical Center, Boston, MA 02111, USA
    Arthritis Rheum 44:2746-9. 2001
    ..To estimate the morbidity, mortality, and lifetime costs of care for rheumatoid arthritis (RA)...
  6. ncbi request reprint Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs
    J B Wong
    Department of Medicine, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    JAMA 280:2088-93. 1998
    ..Chronic hepatitis C (CHC) infection affects nearly 4 million people in the United States. Treatment with interferon alfa-2b has been limited by its cost and low likelihood of long-term response...
  7. pmc Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C
    U Siebert
    Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
    Gut 52:425-32. 2003
    ..Peginterferon alpha-2b plus ribavirin therapy in previously untreated patients with chronic hepatitis C yields the highest sustained virological response rates of any treatment strategy but is expensive...
  8. ncbi request reprint Patient-specific decisions about hormone replacement therapy in postmenopausal women
    N F Col
    Division of Clinical Decision Making, Informatics, and Telemedicine, Department of Medicine, New England Medical Center and Tufts University School of Medicine, Boston, Mass 02111, USA
    JAMA 277:1140-7. 1997
    ..To examine the effect of hormone replacement therapy on life expectancy in postmenopausal women with different risk profiles for heart disease, breast cancer, and hip fracture...
  9. ncbi request reprint Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium
    J B Wong
    Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Boston, Ma U S A Department of Medicine, Divison of Hepatology, Catholic University Hospitals, Leuven, Belgium
    Acta Gastroenterol Belg 65:110-11. 2002
  10. ncbi request reprint Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis
    S J Cheng
    New England Medical Center, Tufts University School of Medicine, 750 Washington St, PO Box 302, Boston, MA 02111, USA
    Transplantation 72:861-8. 2001
    ..CONCLUSIONS: Living-donor liver transplantation should confer a substantial survival advantage for patients with compensated cirrhosis and non-resectable early stage hepatocellular carcinoma...
  11. pmc Strategies for diagnosing and treating suspected acute bacterial sinusitis: a cost-effectiveness analysis
    E M Balk
    Evidence-based Practice Center, Division of Clinical Care Research, Tufts University School of Medicine, New England Medical Center, Boston, MA 02111, USA
    J Gen Intern Med 16:701-11. 2001
    ..Newer, expensive antibiotics are of limited value. Additional testing is not cost-effective. Further studies are needed to find an accurate,low-cost diagnostic test for acute bacterial sinusitis...
  12. ncbi request reprint Cost-effectiveness of anti-tumor necrosis factor agents
    J B Wong
    Division of Clinical Decision Making, Department of Medicine, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Clin Exp Rheumatol 22:S65-70. 2004
    ..This paper reviews the disease burden of rheumatoid arthritis, costs of drug therapy, costs of rheumatoid arthritis and the economics and cost-effectiveness of anti-tumor necrosis factor antibody agents...
  13. ncbi request reprint Using observational data to estimate prognosis: an example using a coronary artery disease registry
    E R DeLong
    Outcomes Research and Assessment Group, Duke Clinical Research Institute, Duke University, Department of Medicine, Biometry Division, Community and Family Medicine, 2400 Pratt Street, Durham, NC 27705, USA
    Stat Med 20:2505-32. 2001
    ..This paper discusses these issues and suggests strategies to deal with them. A proposed methodology is developed, applied and evaluated on a large observational database that has long-term follow-up on nearly 10 000 patients...
  14. ncbi request reprint Fitting nutrition into the medical model: the role of decision analytic cost-effectiveness techniques
    E M Ross
    Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts 02111, USA
    Eur J Clin Nutr 53:S25-8. 1999
    ....
  15. ncbi request reprint Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk
    E A Engels
    Department of Medicine, Tupper Institute, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    Clin Infect Dis 28:256-66. 1999
    ..Ciprofloxacin prophylaxis and particularly intravenous antibiotic therapy provide substantial protection at low neutrophil counts. These results can be used to model management strategies for transplant recipients...
  16. ncbi request reprint The economics of hepatitis C virus
    Bhavesh B Shah
    Division of Clinical Decision Making, Informatics, and Telemedicine, Tufts New England Medical Center, Tufts University School of Medicine, 750 Washington Street 302, Boston, MA 02111, USA
    Clin Liver Dis 10:717-34. 2006
    ..The global economic burden of this disease has yet to be fully realized. In this article the authors discuss the economic burden of hepatitis C, the economics of therapy, and the economics of its prevention and screening...
  17. ncbi request reprint Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C
    John B Wong
    Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Gastroenterol 98:2354-62. 2003
    ..The aim of this study was to examine the economic and clinical effects of evaluating rapid viral response during antiviral therapy for treatment naive chronic hepatitis C patients...
  18. ncbi request reprint Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Hepatology 38:645-52. 2003
    ..Patients who fail to achieve EVR will not clear virus even if an additional 9 months of therapy is received. Therapy can be confidently discontinued in those cases...
  19. ncbi request reprint Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case
    Andreas Maetzel
    Division of Clinical Decision Making and Health Care Research, Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada
    J Rheumatol 30:891-6. 2003
    ..We provide the rationale for each element and discuss how each element has been addressed in published economic evaluations of DMARD...
  20. ncbi request reprint The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK
    Marco Barbieri
    Universitat Pompeu Fabra, Barcelona, Spain
    Pharmacoeconomics 23:607-18. 2005
    ....
  21. ncbi request reprint Intermittent claudication: cost-effectiveness of revascularization versus exercise therapy
    Sybolt O de Vries
    Department of Health Sciences, University of Groningen, The Netherlands
    Radiology 222:25-36. 2002
    ..To compare the costs, effectiveness, and cost-effectiveness of alternative treatment strategies for intermittent claudication...
  22. ncbi request reprint Economics of chronic hepatitis B and hepatitis C
    Arathi Rajendra
    Division of Clinical Decision Making, Department of Medicine, Tufts New England Medical Center, Tufts University School of Medicine, 750 Washington Street, NEMC 302, Boston, MA 02111, USA
    J Hepatol 47:608-17. 2007
    ..This review should help clinicians understand economic issues regarding new drugs and answer questions about whether the clinical benefit provided by a medication justifies its expense...
  23. ncbi request reprint Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies
    John B Wong
    Division of Clinical Decision Making, Department of Medicine, Tufts University School of Medicine, Tufts New England Medical Center, Tupper Research Institute, Boston, Massachusetts 02111, USA
    Pharmacoeconomics 24:661-72. 2006
    ....
  24. ncbi request reprint Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis
    Yoav Golan
    Division of Geographic Medicine and Infectious Diseases, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Ann Intern Med 143:857-69. 2005
    ..Mortality from invasive candidiasis is high. Low culture sensitivity and treatment delay contribute to increased mortality, but nonselective early therapy may result in excess costs and drug resistance...
  25. ncbi request reprint Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy
    John G McHutchison
    Duke Clinical Research Institute, Division of Gastroenterology Duke University, Durham, North Carolina 27705, USA
    Am J Gastroenterol 102:880-9. 2007
    ..In the meantime, physicians must make the best possible use of the available options for managing anemia, especially in select patient groups who are most at risk for anemia and its complications...
  26. ncbi request reprint DEALE-ing with lung cancer and heart failure
    Manu Sondhi
    Department of Medicine, Division of Clinical Desicion Making, Tufts New England Medical Center, Boston, Massachusetts, USA
    Med Decis Making 25:82-94. 2005
  27. ncbi request reprint Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: a decision analysis
    Manish G Amin
    Division of Gastroenterology and Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Liver Transpl 10:1468-75. 2004
    ..At less advanced MELD scores, the survival benefit depends on the risk of PGF associated with the ECD organ...
  28. pmc All dysuria is local. A cost-effectiveness model for designing site-specific management algorithms
    Michael B Rothberg
    Division of Clinical Decision Making, Tufts New England Medical Center and Tufts University School of Medicine, Boston, MA 01199, USA
    J Gen Intern Med 19:433-43. 2004
    ..To determine the cost-effectiveness of management strategies for dysuria in different office settings...
  29. ncbi request reprint Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990
    Murray Krahn
    Toronto General Hospital, ES9 408, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
    Med Decis Making 24:20-9. 2004
    ..To develop a natural history model for chronic hepatitis C virus (HCV) infection to determine allocation of compensatory funds to Canadians who acquired HCV through the blood supply from 1986 through 1990...
  30. ncbi request reprint Estimating hip fracture morbidity, mortality and costs
    R Scott Braithwaite
    Section of Decision Sciences and Clinical Systems Modeling, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    J Am Geriatr Soc 51:364-70. 2003
    ..To estimate lifetime morbidity, mortality, and costs from hip fracture incorporating the effect of deficits in activities of daily living...
  31. ncbi request reprint Simulation of hepatitis C based on a mandatory reporting system
    Markus Sagmeister
    Division of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland
    Eur J Gastroenterol Hepatol 14:25-34. 2002
    ..Hepatitis C is a major cause of liver disease in European countries. We aimed to assess the current and future disease burden of hepatitis C...
  32. doi request reprint Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms
    Craig E Gordon
    Division of Nephrology, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, MA 02111, USA
    Am J Kidney Dis 51:263-77. 2008
    ..We determined the efficacy and harms of interferon (IFN) and pegylated IFN (PEG-IFN) treatment of hemodialysis patients with chronic HCV infection and identified factors associated with these outcomes...